Introduction
Hematologic malignancies result from evolutionary processes driven by stepwise accumulation of genetic mutations with clonal expansion and selection. 1 This model has been refined with the observation of complex, highly subclonal architectures 2 and the finding of simultaneous acquisition of genetic lesions. 3 Exploration of clonal evolution uses various methods, including deep sequencing of bulk tumors 4 and sequencing of single cells or colonies, 5 and needs to integrate the tissue-specific cellular hierarchy to understand why different neoplasms emerging from the same tissue and sharing genetic lesions harbor distinct phenotypes and prognoses. Because of the number of associated gene mutations, 6 ,7 chronic myelomonocytic leukemia (CMML) is a unique model to address clonal architecture in chronic myeloid malignancies.
The characteristic feature of CMML is the accumulation of monocytes, together with dysplastic granulocytes, in the peripheral blood, bone marrow (BM), and spleen. 8 Mutated genes encode signaling molecules (NRAS, KRAS, CBL, JAK2), transcription factors such as RUNX1, epigenetic regulators (TET2, ASXL1, EZH2, UTX, IDH1, IDH2, DNMT3A), and splicing factors (SF3B1, SRSF2, ZRSF2, U2AF35). 6, 7, [9] [10] [11] [12] [13] [14] [15] None of these mutations is specific of the disease, as they were also identified in MPN 16 and in MDS. 17 In MPN, mutations in epigenetic regulators such as TET2 or ASXL1 can be either late events associated with disease progression, or early events that precede mutations in signaling molecules. 5, 18, 19 In MDS, cell dysplasia in diverse myeloid lineage results from various combinations of gene mutations, 17 and knowledge on genotype and phenotype associations is currently limited. 20 The role and place of individual mutations regarding clonal emergence and progression of chronic myeloid malignancies remain poorly understood. The online version of this article contains a data supplement.
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The prognosis of CMML is poor, and aside for the few patients eligible for allogeneic stem cell transplantation, there is no curative treatment. Therapeutic options include hydroxyurea to control myeloproliferation, erythropoiesis-stimulating agents to correct anemia, and hypomethylating agents to delay progression. 8, 21 Novel therapies, such as mitogen-activated protein kinase inhibitors, are in development. The total number of mutated genes seems to be a strong prognostic factor in CMML, 7 suggesting a key role for clonal complexity in leukemogenesis and resistance to therapy.
Here, we explored the clonal architecture of 28 CMML by mutation-specific discrimination analysis of single-cell-derived clones. The genetic classification of individual cells allowed a designation of subclones and the assembly of putative evolutionary trees. We established the sequence of mutation acquisition, the dynamics of clonal expansion during hematopoietic differentiation, and its relationship to the disease phenotype and evolution, both in untreated and in treated patients. Our results suggest that early clonal dominance may specify CMML among other chronic myeloid neoplasms.
Patients and methods

Patients
Blood and BM samples from patients with CMML from Groupe Francophone des Myelodysplasies (study group is described in supplemental Methods) and control BM samples from older (.50 years) patients undergoing hip surgery were prospectively collected after informed consent according to the Declaration of Helsinki. Details are provided in supplemental Methods. The noninterventional study and decitabine trials were approved by the Cochin Hospital and Aulnay-sousBois ethic committees (Comite Consultatif de Protection des Personnes), respectively. fractions were performed for 3 and 12 days, respectively, in minimum essential medium-alpha milieu with 10% fetal bovine serum (FBS) and recombinant human cytokines: stem cell factor (SCF, 50 ng/mL), FLT3-ligand (50 ng/mL), pegylated thrombopoietin (TPO, 10 ng/mL), interleukin-3 (IL-3, 10 ng/mL), interleukin-6 (IL-6, 10 ng/mL), granulocyte-macrophage colony-stimulating factor (GM-CSF, 5 ng/mL), erythropoietin (EPO, 1 IU/ mL), and granulocyte colony-stimulating factor (G-CSF, 10 ng/mL). Detailed protocols are provided in supplemental Methods.
Flow cytometry and cell sorting or cloning
Methylcellulose colony-forming cell (CFC) assays CD34 1 fractions were seeded in triplicate at 250 to 1000 cells per 1-mL culture dish in 2% standard methylcellulose supplemented with 37% FCS, 12% bovine serum albumin, 1% l-glutamine, 10 26 M of b-mercaptoethanol (Sigma-Aldrich, St. Louis, MO) and 20 ng/mL of SCF, 10 ng/mL of IL-3, 3 IU/mL of EPO, and 10 ng/mL of G-CSF. Colonies were counted on day 14. Clonogenic assays for TET2-mutated MDS and MPN are described in supplemental Methods.
Cell cycle analysis
CD34
1 BM cells were incubated with 10 mg/mL of Hoescht 33342 (Life Technologies Invitrogen, Grand Island, NY) for 1 hour at 37°C in minimum essential medium-alpha milieu with 10% FBS and cytokines (50 ng/mL of SCF, 50 ng/mL of FLT3-ligand, 10 ng/mL of TPO, 10 ng/mL of IL-3, and 10 ng/mL of IL-6). The cells were then stained, acquired, and analyzed as described in supplemental Methods.
Serial replating assays
Clones generated at day 12 in liquid culture in the above-mentioned conditions were individually seeded in 96-well plates in 2% standard methylcellulose with 37% FCS, 12% bovine serum albumin, 1% lglutamine, 10 26 M of b-mercaptoethanol and 20 ng/mL of SCF, 10 ng/mL of IL-3, and 10 ng/mL of G-CSF. At day 14, wells containing cell clusters (>20 cells) were counted, picked, washed, and reseeded in 96-well methylcellulose plates in similar conditions. This process was repeated 5 times. Results are a percentage of the initial number of clones.
Genotyping of clones and colonies
DNA from liquid-culture clones or methylcellulose colonies was prepared as described previously. 22 Mutational status was analyzed by mutationspecific fluorescent competitive probes with TaqMan real-time polymerase chain reaction (PCR) on an ABI 7500 (Applied Biosystems, Foster City, CA). Primers and probes for each mutation are detailed in supplemental Methods. Equivocal results were validated by sequencing.
Real-time quantitative PCR
Total RNA isolated with Trizol (Life Technologies) was reverse-transcribed with Superscript Vilo (Life Technologies Invitrogen). Real-time PCR was performed on an Applied Biosystems 7500 Fast thermocycler using the SyBrGreen protocol (Applied Biosystems). Primers sequences will be given on request. These subpopulations were cultured at 1 cell per well in liquid medium for 12 days in the presence of a broad panel of cytokines (SCF, FLT3-L, TPO, IL-3, IL-6, G-CSF, GM-CSF, and EPO) to maximize cloning efficacy and limit biases in clonal representation. We then collected the clones and performed TaqMan discrimination analysis specifically designed for each individual mutation identified initially in PB CD14
1 cells (supplemental Figure 2A ).
This strategy allows a faithful representation of clonal repartition for the following reasons: (1) The cloning efficacy of CD34 In all 28 patients, at least one of the mutations was found in more than 75% of PB CD34
1
/CD38
2 or BM HSC clones ( Figure 1A ), without significant difference between CMML-1 and CMML-2 cases. In 9 of 28 patients with sufficient materiel, 7 of 16 studied mutations originally detected in peripheral blood CD14 1 cells were also found in sorted CD3
1
, including 2 of 7 in TET2, 2 of 3 in ASXL1, 1 of 2 in CBL, 1 of 1 in JAK2, and 1 of 1 in KRAS but 0 of 2 in RUNX1 (examples in Figure 1B ). Taken together, our results point out an early amplification of the CMML clone at the CD34 Figure 1D ). The resulting succession of mutations in the 28 patients is recapitulated in Table 1 . In 4 cases, an order of acquisition could not be assigned to 2 mutations (all involving a splice gene) because they were detected in the same clones. Although the order acquisition of the mutations was not fixed, mutations in TET2 or ASXL1 preceded mutations in signaling genes in most cases. We then studied the dynamics of clonal architecture during myeloid differentiation by comparing clonal frequencies in sorted HSC, MPP, CMP, and GMP. We found an overrepresentation of subclones with greater number of mutations in GMP compared with HSC/MPP (examples in Figure 1C ). In 14 of 19 patients with more than 1 mutation and sufficient numbers of assessable clones, the first event was present in more than 85% of HSC/MPP, without significant change in the frequency in CMP and GMP, underscoring the early dominance of the leukemic clone, whereas the second event was significantly more frequent in GMP than in HSC/ MPP ( Figure 1E ). Altogether, our results show linear acquisition of mutations, clonal dominance of the malignant clone at the CD34 1 / CD38 2 stages (HSC and MPP) of hematopoiesis, and further selection of the more mutated subclones during the early steps of myeloid differentiation until the GMP stage. This trend suggests that secondary mutations may provide an advantage to the clone during myeloid differentiation.
Clonal branching through loss of heterozygosity
We next took advantage of information on heterozygosity and homozygosity of mutations to refine the evolutionary trees of the 19 patients with 2 or more mutations. In 10 patients, the architecture was strictly linear and mosaicism was identified in 1 patient. In the remaining 8 patients, we identified subclones with loss of heterozygosity (LOH) of mutations in CBL (n 5 3, including 2 with a concomitant LOH in the TET2 or SF3B1 loci, respectively), KRAS, JAK2, TET2, and ZRSR2 (each n 5 1), giving rise to single or multiple branching in the clonal architecture (example in Figure 2A , summarized in Table 1 ). The detection of subclones with reversion of a mutation to wild-type status suggested a mitotic recombination event as the origin of LOH. This hypothesis was assessed by taking advantage of an informative intronic single nucleotide polymorphism (SNP, rs77741206G/A) located 46 base 
/CD90
1 , noted with an asterisk) or peripheral blood immature cells (CD34 1 /CD38
2 ) of 28 patients (detailed in Table 1 ) were cultured at 1 per well in liquid medium for 12 days in the presence of cytokines, then collected, and assessed by allele discrimination analysis of each individual mutation initially identified in peripheral blood CD14 
SF3B1 c.1756G.C (p.D586H) in 1 patient (UPN #638). The SNP was heterozygous in 9 clones with a heterozygous SF3B1 mutation, whereas symmetric LOH of rs77741206 was detected in 9 clones with a wild-type or homozygous SF3B1 mutation ( Figure 2B ). The clonal diversity generated by these branched architectures was also submitted to clonal selection during myeloid differentiation to the CMP and GMP stages (example in Figure 2C ).
To confirm that the clonal architecture identified by focusing on 18 frequently mutated genes holds true when analyzing the full spectrum of genetic lesions, we performed whole-exome sequencing of peripheral CD14
1 cells in a patient with TET2 and U2AF35
mutations. We identified 14 additional gene mutations confirmed by Sanger sequencing, including a noncanonical KRAS mutation (K117R). All mutations were heterozygous except the homozygous TET2 deletion. Again, mutation-specific discrimination analysis of CD34 1 colonies after liquid culture showed the linear accumulation of mutations, with only minor subclones possibly resulting from a mitotic recombination affecting the KRAS locus (supplemental Figure 4) . Altogether, the dominant clone mostly results from sequential waves of mutation acquisition and expansion, with minor subclones probably generated by homologous recombination at specific sites.
Clonal architecture is dynamic and is selectively affected by therapy
We analyzed the fate of clonal heterogeneity in the face of temporal evolution of CMML, either in untreated patients or in patients with currently available therapies (detailed in supplemental Table 1 ). In an untreated and clinically stable patient analyzed twice at a 12-month interval, the proportion of clones with 2 mutations increased significantly in HSC/MPP (UPN #507; Figure 3A) . A similar evolution was noted, with the same interval in a patient receiving hydroxyurea (UPN #516; Figure 3B ). In a patient with stable disease under hypomethylating therapy (UPN #550), we observed the amplification of the more mutated clone, which harbors an ASXL1 mutation ( Figure 3C ). It is surprising to note that when UPN #506 achieved erythroid improvement with an erythropoiesis-stimulating agent (after natural evolution depicted in Figure 3B ), a re-expansion of wild-type hematopoiesis was observed in the CD34
1
/CD38
2 compartment, although the selective advantage of the more mutated clone persisted during myeloid differentiation ( Figure 3D ). In UPN #752 with a somatic mosaicism between KRAS and NRAS mutations, achievement of a transient control of myeloproliferation and circulating blast counts with an investigational mitogen-activated protein kinase kinase inhibitor only resulted in a shift of the equilibrium between the 2 clones, with a slight expansion of the KRAS-mutated clone at the expanse of the NRAS mutation (supplemental Figure 5) . Finally, 1 patient (UPN #632) with proliferative CMML achieved partial response with intensive chemotherapy, converted to complete response after hypomethylating therapy, then underwent allogeneic stem cell transplantation and experienced a relapse 6 months later. Sequential analysis of his clonal architecture showed a reduction of the NRAS-mutated clone by chemotherapy and hypomethylating therapy, allowing the expansion of the ancestral TET2/SRSF2-mutated clone. Nonetheless, the more mutated clone persisted and regained dominance at relapse ( Figure 3E ).
GMP are quantitatively and qualitatively normal in CMML
To understand the relationship between the clonal architecture and the phenotype of CMML, we sought to analyze the cellular mechanisms driving the emergence from the CD34 1 compartment of the granulomonocytic expansion of CMML. Because clonal dominance, notably regarding secondary mutations, is achieved at the GMP stage ( Figure 1E ), we quantitatively and qualitatively analyzed this compartment. The differentiation potential of GMP was assessed with the gold-standard 14-day methylcellulose assay, in the presence of FBS and a restricted panel of cytokines (SCF, IL-3, G-CSF, and EPO) compared with previous experiments (Figure 1-3) . This panel allowed comparison of the granulomonocytic and potential for erythroid differentiation of all CD34 1 fractions, and avoided the use of GM-CSF whose activity is heterogeneous in CMML. [24] [25] [26] The potential for self-renewal was assessed by serial replating in similar conditions without EPO to focus on granulomonocytic progenitors. By flow cytometry, the percentage of GMP among BM CD34 1 cells was not significantly different in 33 patients with CMML (with a mutation spectrum representative of the entire population, not shown) and 15 age-matched healthy participants ( Figure 4A ). The ability to form granulomonocytic colonies in methylcellulose was similar in patients and healthy control participants ( Figure 4B ). Cell cycle analysis did not identify any significant change in patient cells ( Figure 4C ), and serial replating did not demonstrate a strong increase in their self-renewal capability ( Figure 4D ). Overall, no systematic quantitative or qualitative alteration of GMP was identified in CMML, suggesting that the granulomonocytic expansion characteristic of this disease may have appeared at earlier stages of myeloid differentiation.
CMP and MPP undergo premature granulomonocytic differentiation in CMML
Contrasting with the normal GMP fraction, the percentages of CMP and MPP were higher in patients with CMML than in healthy control participants ( Figure 5A ). When cultured in methylcellulose in similar conditions as GMP, both CMP and, to a lesser extent, MPP demonstrated an increased ability to form granulomonocytic colonies at the expense of erythroid colonies ( Figure 5B ). Similar results were found when CMP were cultured as single cells in a liquid medium for 12 days in the presence of a larger panel of cytokines (SCF, FLT3-L, TPO, IL-3, IL-6, G-CSF, GM-CSF, and EPO), with a strong increase in the percentage of granulomonocytes (CD14 1 and/or CD15 1 and/or CD24 1 ) at the expense of erythroid (GPA 1 ) clones (supplemental Figure 6B) , despite unchanged cloning efficacy (supplemental Figure 6A) . Analysis of mutations in granulomonocytic and erythroid colonies obtained by culturing CMP from 3 patients showed a similar repartition of the mutated alleles in the 2 types of colonies, demonstrating that the majority of erythroid colonies belong to the most mutated subclone (not shown). Short-term (3-day) culture of CMP in liquid medium followed by immunophenotypic analyses showed their increased ability to mature into GMP at the expense of MEP ( Figure 5C ). The functional relevance of CD34 1 cell immunophenotyping after this 3-day culture was validated by resorting GMP, MEP, and CMP at day 3 and assessing their clonogenic potential (supplemental Figure 6C ). Gene expression analysis revealed an For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From increased expression of PU.1 with nonsignificant changes in the level of GATA1, CEBPA, and CEBPB in CMP sorted from CMML compared with those from healthy control participants ( Figure 5D ; supplemental Figure 6D ). Finally, the proportion of granulomonocytic colonies differentiating from CMP at the expense of erythroid colonies correlated inversely with patient hemoglobin level ( Figure 5E ). Altogether, these results suggest that immature pluripotent progenitors (CMP and, to a lesser extent, MPP) are skewed toward granulomonocytic differentiation in CMML.
Early clonal dominance of TET2 mutations leads to granulomonocytic hyperplasia
To unravel a link between early clonal dominance and myeloid differentiation skewing in CMML, we focused on TET2, which is the most frequently 6, 7, 27 and early (Table 1 ) mutated gene in CMML known to date. TET2 is also mutated in 15% to 25% of cases of MDS and MPN, 5, 27, 28 where granulomonocytic hyperplasia is absent (MDS) or variable (MPN). We interrogated the stage of expansion of the TET2-mutated clone in colonies generated from CD34 Table 2 ). We observed a significant correlation between the proportion of cells with mutated TET2 at the CD34 Figure 6C ). Altogether, early dominance of the TET2-mutated clone in the immature CD34 1 /CD38 2 compartment may participate in the granulomonocytic skewing that defines CMML.
Discussion
CMML shares with MPN, MDS, and other MDS/MPN several gene mutations. Whereas a driver oncogenic mutation leading to the constitutive activation of intracellular signaling pathways has been identified in most MPN 16 and in juvenile myelomonocytic leukemia, 29 the driver oncogenic events involved in CMML are less clearly identified. TET2, SRSF2 (which is often associated to TET2), 6, 13 and ASXL1 are the most frequent genetic events in CMML. 6, 7, 14, 15 The number of mutated genes is a strong prognostic factor in CMML. 7 This prompted the investigation of the clonal architecture of genetic lesions in 28 cases of CMML, Table  1 for details). (A) UPN #516: TET2 K4503, NRAS G12D. (B,D) UPN #507: TET2 S7163, CBL W408R, SRSF2 P95H. C. UPN #550: TET2 D1242TfsX11, RUNX1 Y376LfsX197, SRSF2 P95H, ASXL1 E635RfsX15.(E) UPN #632: TET2 N1156I; NRAS A59G; SRSF2 P95H. The total number of interrogated clones is indicated on the top of the bars. Missing fractions represent phenotypes underrepresented in posttreatment samples. Note that in UPN #632, showing RAEB-2 rapidly evolving to AML at relapse, the LMPP and GMP fractions were dominant, as previously described. 47 12 mo, 12 months untreated evolution; ASCT, Allogeneic Stem Cell Transplantation; ESA, ErythropoiesisStimulating Agent; HMA, Hypomethylating Agent; HY, Hydroxyurea; IC, Intensive Chemotherapy; LMPP, Lymphoid-primed multipotent progenitors; Re, AML Relapse.
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showing that gene mutations are sequentially acquired, leading to a mostly linear clonal architecture, with frequent branching through LOH resulting from mitotic recombinations. Early clonal dominance at the CD34
1
/CD38
2 stage of hematopoiesis, especially dominance of TET2-mutated cells, is a key feature of the disease that is accompanied by myeloid differentiation skewing toward the granulomonocytic lineages, whereas additional genetic events rapidly confer a selective advantage to the clone during myeloid differentiation. Tumor genetic heterogeneity was initially thought to evolve through sequential, "linear" acquisition of collaborating mutations, followed by waves of clonal expansion. 30 Recent analyses in acute leukemias revealed more complex, oligoclonal models. 2, 4, 31 Here, we show that the clonal architecture of CMML may reconcile both models (ie, a mostly linear acquisition of the mutations), with a few ramifications likely the result of homologous recombinations.
9 LOH occurs at loci-encoding genes from all classes (epigenetic, splicing, and signaling), though homozygous clones achieving clonal dominance are mostly restricted to the TET2 and CBL genes. 5, 9 Next-generation sequencing identifies an average of 10 somatic exonic mutations in MDS, all of which arise in the same CD34 1 cell. 4, 32 In all but one of the 28 studied cases of CMML, all mutations were present in at least one CD34 1 leukemic clones from a representative patient with CMML followed by clonal architecture analysis identified sequential waves of acquisition of mutations, each wave including 1 presumed driver oncogenic lesion, such as TET2, U2AF35, or KRAS mutations. Sequential analyses demonstrated that, aside from allogeneic stem cell transplantation, all current therapeutic strategies modulate, rather than eradicate, the leukemic clone. The reconstructed phylogenetic trees also allowed ordering of the sequence of acquisition of the studied mutations, except in 4 cases, raising the possibility that 2 mutations were concomitantly gained in those cases. Why certain mutations, such as those in TET2 and SRSF2, are often associated remains uncertain, but the finding that their order of acquisition is biased but not stereotyped suggests that their association arises from functional cooperation. 33 Clonal dominance is a heterogeneous feature in myeloid malignancies. For example, clonal expansion of JAK2 V617F mutations occurs in earlier progenitors in myelofibrosis 34 than in polycythemia vera, 22 a difference attributed to the role of additional mutations in TET2 5 or ASXL1. 19 Here, we show that early clonal dominance of initial mutations in CD34
1
/CD38
2 immature progenitors is a key feature of CMML. Clones harboring only part of the oncogenic lesions persist in this compartment, whereas the fully mutated leukemic clone harboring secondary lesions is further selected during myeloid differentiation to the GMP stage. Mutations affecting cell signaling such as JAK2, NRAS, or KRAS mutations, or LOH of a heterozygous CBL mutation, may favor this differentiation-associated selection, as JAK2 V617F does in MPN. 22 Our strategy to establish clonal architecture, based on the tracking of recurrent mutations in single-cell-derived colonies after in vitro culture, had 2 limitations. First, it did not address the full spectrum of genetic aberrations present in the tumor. Founder mutations could have preceded what we detect as "primary" events. If this is the case, early clonal dominance would be of even greater magnitude than reported. In the unique patient studied by whole exome, however, the 
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TET2 "primary" event was present in the founder clone, in accordance with the finding of TET2 mutations in preleukemic HSC in AML 35 and in HSC of older patients with clonal, but nonmalignant, hematopoiesis. 36 Second, in vitro culture may introduce biases in clonal representation. However, validation of single-cell-derived colonies genotyping has been reported in AML 35 and was confirmed in our present study. Next-generation sequencing represents the major alternative strategy to assess clonal architecture, but it is either applied to bulk samples 4 with the risk of missing mosaic subclones, or to amplified DNA from single cells, thus introducing other biases and limiting resolution with current techniques. 37, 38 Because genes mutated in CMML are also found in other myeloid malignancies, we next sought to understand the relationship between the clonal architecture of CMML and the emergence of its distinctive phenotypic trait, namely granulomonocytic hyperplasia. Whereas analysis of sorted progenitors did not identify alterations of the GMP compartment, the CMML BM CD34
1 compartment was enriched in CMP and MPP with a skewed myeloid differentiation (ie, an enhanced capability to form granulomonocytic colonies at the expense of erythroid colonies). This skewed myeloid differentiation could result from biased lineage decision and/or differential amplification of granulomonocytic and erythroid progenitors after lineage commitment, a question recently addressed in normal hematopoietic differentiation by single-celltracking studies. 39, 40 Inhibition of TET2 expression in CD34 1 cells has been shown to promote granulomonocytic differentiation in vitro and in vivo, 23, 41, 42 yet TET2 mutation allele burden in total BM-nucleated cells (representing differentiated cells) seems comparable in MDS, which lacks monocytosis, and CMML. 27 To elucidate this paradox, we analyzed the amplification of TET2 mutations in CD34 1 progenitor cells from patients with either MDS, or those with JAK2 V617F MPN, where monocyte count is variable. 43 In these diseases, we uncovered a specific correlation between amplification of TET2-mutated cells in the immature CD34 (Figure 7) . According to this model, early dominance of the mutated clone, in particular, in the presence of a TET2 mutation, accounts for the accumulation of monocytes in CMML. In other chronic myeloid malignancies such as MDS or MPN, TET2 mutations may reach clonal dominance at later stages of myeloid differentiation (eg, because of additional mutations such as JAK2 V617F ). Differences in the dynamics of clonal amplification of TET2 mutations could be explained by either specific combinations of mutations (eg, TET2/SRSF2 in CMML), 6 ,13 their occurrence in distinct subsets of HSC, 44 or a stochastic effect of TET2 in the initially mutated cell (Figure 7 ). These models could explain why monocytosis can develop in the course of MDS 45 or MPN 46 without acquisition of novel mutations. In addition to providing hypotheses to explain the disease phenotype, analyses of clonal architecture may allow defining therapeutic strategies that improve disease control and possibly achieve clonal eradication by targeting the first genetic aberrations that accumulate in immature progenitors. 
